Clearmind Medicine Inc.

CMND

CA1850535016

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2026-02-13 pm EST			5-day change	1st Jan Change
1.120 ^USD	+2.75%		-9.68%	-38.12%

Feb. 09	Clearmind Medicine announces additional topline positive safety results reinforcing favorable profile of cmnd-100 in ongoing Phase I/Iia clinical trial	RE
Feb. 09	Clearmind Medicine Announces Additional Topline Positive Safety Results Reinforcing Favorable Profile of CMND-100 in Ongoing Phase I/IIa Clinical Trial	CI

Clearmind Medicine announces successful completion of second cohort enrollment

Published on 12/16/2025 at 10:07 am EST

Reuters

Latest news about Clearmind Medicine Inc.

Feb. 09	Clearmind Medicine announces additional topline positive safety results reinforcing favorable profile of cmnd-100 in ongoing Phase I/Iia clinical trial	RE
Feb. 09	Clearmind Medicine Announces Additional Topline Positive Safety Results Reinforcing Favorable Profile of CMND-100 in Ongoing Phase I/IIa Clinical Trial	CI
Feb. 06	Polyrizon Ltd. Signs an Agreement to Develop Intranasal Proprietary Non-Hallucinogenic Neuroplastogen Formulation	CI
Feb. 06	Clearmind Medicine Enters into Development Agreement to Advance Intranasal Formulation for its Proprietary Non-Hallucinogenic Neuroplastogen MEAI	CI
Feb. 06	Clearmind Medicine enters development agreement for intranasal formulation of proprietary nonhallucinogenic neuroplastogen MEAI	RE
Jan. 20	Clearmind Medicine Inc. Reports Earnings Results for the Full Year Ended October 31, 2025	CI
Jan. 19	Clearmind Medicine Inc. Auditor Raises 'Going Concern' Doubt	CI
Jan. 14	Clearmind Medicine Announces Successful Completion of Treatment in All Patients of the Second Cohort in Ongoing Phase I/IIa Clinical Trial for CMND-100	CI
Jan. 14	Clearmind Medicine Inc - Topline results from second cohort of CMND-100 expected in coming months	RE
Dec. 31	Clearmind Medicine Says Nasdaq Compliance Regained on Minimum Bid Price Rule	MT
Dec. 16	Clearmind Medicine announces successful completion of second cohort enrollment	RE
Dec. 16	Clearmind Medicine Inc. Announces Successful Completion of Second Cohort Enrollment in Ongoing FDA-Approved Phase I/IIa Trial for CMND-100	CI
Dec. 12	Clearmind Medicine Regains Compliance With Nasdaq's Minimum Stockholders' Equity Requirement	MT
Dec. 03	Clearmind Medicine Inc files for offering of up to 16 million common shares - SEC filing	RE
Dec. 02	Clearmind Medicine Advances CMND-100 to Dosing Phase at Hadassah Medical Center in Ongoing Phase I/IIa Clinical Trial for Alcohol Use Disorder	CI

Clearmind Medicine Inc. is a psychedelic pharmaceutical biotech company. The Company is focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorders. The Company researches and develops psychedelic-based compounds and attempts to commercialize them as regulated medicines, foods, or supplements. The Companyâ€™s intellectual portfolio consists of 15 patent families, including 27 granted patents and 24 pending applications. The portfolio spans a range of jurisdictions, including the United States, Europe, India, and China.

Employees

Sector

Biotechnology & Medical Research

Calendar

Mar. 24 - Q1 2026 Earnings Release (Projected)

More about the company